Update on the pathogenesis and treatment of Kaposi sarcoma

Current Opinion in Oncology

Volumn 12, Issue 2, 2000, Pages 174-180

  Mitsuyasu, Ronald T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ACICLOVIR; ALITRETINOIN; ANTIVIRUS AGENT; BLEOMYCIN; DAUNORUBICIN; DOXORUBICIN; FOSCARNET; FUMAGILLOL CHLOROACETYLCARBAMATE; GANCICLOVIR; IM 862; ISOTRETINOIN; PACLITAXEL; RECOMBINANT ALPHA2A INTERFERON; RETINOIC ACID; THALIDOMIDE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CRYOTHERAPY; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; PHOTOCHEMOTHERAPY; SARCOMA, KAPOSI;

EID: 0034517180     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200003000-00013     Document Type: Review

References (54)

1. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/adolescent spectrum of HIV disease project group
2. Seroprevalence of human immunodeficiency virus type 1 infection in childhood malignancy in Zimbabwe
3. Evidence for concurrent epidemics of human herpesvirus 8 and human immunodeficiency virus type 1 in US homosexual men: Rates, risk factors and relationship to Kaposi's Sarcoma
4. Identification of herpesvirus-like DNA sequences in AIDS associated Kaposi's sarcoma
5. Herpesvirus-like DNA sequences detected in endemic, classical, iatrogenic and epidemic Kaposi's sarcoma biopsies
6. Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients
7. Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma
8. A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma
9. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus related latent nuclear antigens before the development of Kaposi's sarcoma
10. Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases
11. Clinical aspects of AIDS-related Kaposi's sarcoma
12. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development
13. Inflammatory cytokines induce the expression of basic fibroblast growth factor (bFGF) isoforms required for the growth of Kaposi's sarcoma and endothelial cells through the activation of AP-1 response elements in the bFGF promoter
14. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6
15. Kaposi's sarcoma-associated herpesvirus: Epidemiology, virology, and molecular biology
16. Chemokines activate Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture
17. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells
18. G protein coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator
19. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma
20. Increased human herpesvirus-8 copy number and viral gene expression in AIDS-Kaposi's sarcoma patients peripheral blood mononuclear cells cultured in the presence of inflammatory cytokines
21. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha 5 beta 1 and alpha V beta 3 integrins and by mobilizing sequestered basic fibroblast growth factor
22. HIV-1 Tat induces the expression of the interleukin-6 (IL-6) gene by binding to the IL-6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors
23. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha V beta 3 integrin
24. HLA studies in acquired immune deficiency syndrome patients with Kaposi's sarcoma
25. HLA and Kaposi's sarcoma in solid organ transplantation
26. Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996
27. Epidemiology of Kaposi's sarcoma in Sweden prior to the acquired immunodeficiency syndrome
28. Differences in androgen of HIV positive patients with and without Kaposi's sarcoma
29. Human herpesvirus 8 and its role in the genesis of Kaposi's sarcoma
30. Radiotherapy in the management of epidemic Kaposi's sarcoma: A retrospective study of 643 cases
31. Medical management of AIDS patients with Kaposi's sarcoma
32. Kaposi's sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy
33. Cryosurgery in dermatology
34. Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome
35. Antiproliferative effects of retinoic compounds on Kaposi's sarcoma cells
36. Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation
37. Retinoic acid inhibits interleukin-6 induced macrophage differentiation and apoptosis in a murine hematopoietic cell line, Y6
38. Phase I/II study of intermittent all-transretinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma
39. Topical treatment of epidemic Kaposi's sarcoma with all-trans-retinoic acid
40. Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: Results of a sequential non-randomized phase II trial
41. Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposi's sarcoma
42. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical aliretinoin (9-cis-retinoic acid) gel
43. Oral LGD1057 is active in AIDS related Kaposi's sarcoma: An AIDS associated malignancy group trial (AMC-002)
44. Management of AIDS-associated Kaposi's sarcoma: A multidisciplinary perspective
45. Randomized phase III trial of liposomal daunorubicin (DaunoXome) versus doxorubicin, bleomycin, vincristine (ABV) in AIDS-related Kaposi's sarcoma
46. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma
47. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma
48. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma
49. Interferon-alpha: Evolving therapy for AIDS-associated Kaposi's sarcoma
50. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
51. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV-8 titer
52. Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trials Group study
53. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus
54. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS